MINSTmelatoninNCT07926282
Adjunctive Melatonin Gel With MINST on GCF Galectin-3 and IL-1 in Stage III-IV Periodontitis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Clinical Attachment Level (CAL)
Timeframe: Baseline, 1 month, and 2 months after treatment
Probing Pocket Depth (PPD)
Timeframe: Baseline, 1 month, and 2 months after treatment
Full-Mouth Plaque Score (FMPS)
Timeframe: Baseline, 1 month, and 2 months after treatment
Full-Mouth Bleeding Score (FMBS)
Timeframe: Baseline, 1 month, and 2 months after treatment
Gingival Recession (GR)
Timeframe: Baseline, 1 month, and 2 months after treatment
Gingival Crevicular Fluid Galectin-3 Level
Timeframe: Baseline, 1 month, and 2 months after treatment
Gingival Crevicular Fluid Interleukin-1 (IL-1) Level
Timeframe: Baseline, 1 month, and 2 months after treatment
Patient Satisfaction
Timeframe: 2 months after treatment
Arms and interventions
MINST + Melatonin GelExperimental
Patients with Stage III-IV periodontitis will receive minimally invasive non-surgical periodontal therapy (MINST) followed by intra-pocket application of melatonin gel once weekly for 4 weeks
MINST AloneActive comparator
Patients with Stage III-IV periodontitis will receive minimally invasive non-surgical periodontal therapy (MINST) only.
Drugs: Melatonin gel
Procedures: Minimally Invasive Non-Surgical Therapy (MINST)